Close
Close
Treatment Database
N-(1,3-dimethyl-1H-pyrazole-4-sulfonyl)-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide/tezacaftor/ivacaftor
Trade Name not avaiable
Orphan Indication Cystic Fibrosis
USA Market Approval
USA Designation Date 29-08-2018
Sponsor Vertex Pharmaceuticals Inc.
50 Northern Avenue
Boston, Massachusetts, 02210
More about Cystic fibrosis
Free Newsletter
Treatment News
Related Videos